CAR-T

TCR-T · TIL · NK · Treg

Auto

Vein-to-Vein CMC & COI Systems

Allo

Scale-Up & Off-the-Shelf Distribution

IND–BLA

Full Lifecycle · CBER / OTAT

Cell Therapy Expertise CMC Consulting Built Around Living Cell Products

CAR-T, TCR-T, TIL, NK, and Treg programs each carry distinct manufacturing demands, CQA profiles, and regulatory expectations. DES Pharma brings consulting depth across all major modalities and both manufacturing models, without conflating them.

Autologous programs demand patient-specific scheduling, chain of identity, and vein-to-vein time management. Allogeneic programs require master cell banking, scalable closed-system expansion, and off-the-shelf distribution readiness. Cell therapy CQAs (viability, CAR expression, VCN, potency) are defined by manufacturing decisions made in development, not corrected downstream.

Our ServicesEnd-to-End Cell Therapy
CMC Support

Six coordinated service areas covering the full development and
commercialization lifecycle of cell therapy programs.

Program & Process Development

From leukapheresis qualification and transduction platform selection through cryopreservation, tech transfer, process characterization, and PPQ readiness.

Analytics & Quality Control

ATP/TPP-aligned analytical programs: flow cytometry, CAR expression, potency assays, VCN by ddPCR, RCL/RCR, and rapid lot release for time-constrained autologous programs.

Supply Chain & Procurement

Apheresis qualification, chain of identity systems, GMP lentiviral vector supply, ISTA-7E qualified cryogenic logistics, CDMO selection, and slot-based scheduling.

Quality Assurance

GMP and cGTP compliance, patient-specific batch records, COI/COC QA, rapid lot release, deviation and CAPA management, supplier qualification, and CBER/OTAT inspection readiness.

Medical Safety & Pharmacovigilance

CRS and ICANS safety oversight, REMS program design, DSMB support, long-term follow-up protocols, SUSAR reporting, and inspection-ready PV systems for cell therapy programs.

Phase-Appropriate Across the Lifecycle

We calibrate scope, depth, and deliverables to where you are in development, from first IND preparation through BLA submission and post-approval lifecycle management.

Why DES Pharma Built for the Demands of Living Cell Products

Cell therapy programs fail at the intersection of biology, operations, and regulation, not because the science is wrong, but because the systems around it were not built for a living product. DES Pharma closes that gap with modality-specific depth across every function.

Autologous Operational Depth

Chain of identity as a patient safety obligation. Slot-based manufacturing scheduling. Rapid lot release designed around the infusion date. We build autologous systems that hold up under CBER/OTAT review.

Allogeneic Scale-Up

Master cell banking, closed-system scalable expansion, and off-the-shelf distribution readiness. Allogeneic QA frameworks are built separately from autologous programs because the two are operationally distinct.

Cryogenic & Supply Chain

ISTA-7E qualified LN2 dry shippers, cold-chain validation, and GMP lentiviral vector supply strategy. A cold chain excursion in autologous cell therapy is irreversible. Prevention is the only strategy.

CBER / OTAT Submissions

IND sections, RMAT designation support, Type B meetings, BLA CMC packages, and pre-approval inspection preparation: documentation calibrated to OTAT reviewer expectations, not transplanted from protein analytics programs.

How We WorkHow DES Pharma Engages on Cell Therapy Programs

We begin by understanding your program’s specific context (molecule, stage, manufacturing model, and regulatory history) before recommending a CMC strategy.

Program Assessment & Gap Analysis

Review your existing CMC data, IND documentation, and manufacturing history to identify gaps against phase-appropriate expectations and your CBER/OTAT regulatory pathway.

CMC Strategy & Roadmap

Define a fit-for-purpose plan covering process development, analytics, supply chain, QA, and regulatory filing timeline, integrated with your clinical plan and manufacturing model.

Technical Execution & Oversight

Lead, support, or oversee workstreams: from directing CDMO activities and reviewing batch data to authoring IND sections and BLA CMC modules in real time.

Clinical Supply Chain Consulting

Regulatory References

21 CFR 1271

HCT/P registration, cGTP, chain of identity & donor eligibility for cell therapy products

21 CFR 600

Biological product standards: lot release, potency, and identity for BLA-regulated cell therapies

ICH Q5A · Q5E

Viral safety and comparability for gene-modified cell therapy products

RMAT

Regenerative Medicine Advanced Therapy: expedited CBER review with enhanced Type B meeting access

CBER Potency

2011 CBER Guidance: potency assay strategy from surrogate to mechanism-based for cell therapy programs

Get Started Ready to Advance Your Cell Therapy Program?

Whether you are preparing your first IND or finalizing a BLA submission, our consultants are ready to assess your program and identify the highest-value areas for support.